In a randomized open-label 2-arm study of 148 men with T2D, sensorimotor polyneuropathy and erectile dysfunction (IIEF-5 < 21), participants received standard of care with insulin, rosuvastatin 10 mg and α-lipoic acid 600 mg IV; the treatment arm additionally received intramuscular NGF 18 mg daily for the duration of hospitalization, mean 10 days, range 3–27. The gene discussed is INS; the disease is type 2 diabetes mellitus.